What is it about?
Cancer immunotherapy targets the immune cells so that they can more efficiently attack tumor cells. Not every patient benefits, however, because some tumors can turn off the activity of the immune cells against them. It is not well understood why some tumors respond better than others to immunotherapy. This study analyzed immune cells from lung cancer patients who were treated with immunotherapy, to see what the differences might be between patients with tumors which responded better than for the other patients. The analysis applied a comprehensive set of machine learning methods that could automatically detect these differences.
Featured Image
Why is it important?
The study found that there exist combinations and proportions of immune cell types that can accurately indicate whether a patient’s tumor will respond well or not to the immunotherapy. In particular, markers associated with B-cells were identified as key features that were different between the patient groups. Next steps will be to evaluate the study findings in a larger group of patients, with the ultimate goal to help select the best immunotherapy for each and every patient.
Perspectives
Read the Original
This page is a summary of: Prediction of lung cancer immunotherapy response via machine learning analysis of immune cell lineage and surface markers, Cancer Biomarkers, July 2022, IOS Press,
DOI: 10.3233/cbm-210529.
You can read the full text:
Contributors
The following have contributed to this page